Apex Biotechnology Past Earnings Performance
Past criteria checks 2/6
Apex Biotechnology has been growing earnings at an average annual rate of 8%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been declining at an average rate of 4% per year. Apex Biotechnology's return on equity is 5.9%, and it has net margins of 5.8%.
Key information
8.0%
Earnings growth rate
8.0%
EPS growth rate
| Medical Equipment Industry Growth | 11.5% |
| Revenue growth rate | -4.0% |
| Return on equity | 5.9% |
| Net Margin | 5.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings
Nov 21
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around
Aug 06Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings
Mar 21Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business
Apr 17Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?
Mar 10Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?
Feb 17A Look At Apex Biotechnology's (TPE:1733) Share Price Returns
Jan 27
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture
Jan 06These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?
Nov 22Revenue & Expenses Breakdown
How Apex Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,808 | 105 | 229 | 159 |
| 30 Jun 24 | 1,711 | 109 | 230 | 162 |
| 31 Mar 24 | 1,691 | 109 | 227 | 163 |
| 31 Dec 23 | 1,677 | 116 | 226 | 163 |
| 30 Sep 23 | 1,775 | 144 | 232 | 166 |
| 30 Jun 23 | 1,968 | 170 | 234 | 165 |
| 31 Mar 23 | 2,159 | 172 | 231 | 169 |
| 31 Dec 22 | 2,244 | 182 | 235 | 165 |
| 30 Sep 22 | 2,297 | 220 | 233 | 158 |
| 30 Jun 22 | 2,201 | 220 | 224 | 157 |
| 31 Mar 22 | 2,077 | 214 | 220 | 151 |
| 31 Dec 21 | 2,132 | 202 | 213 | 153 |
| 30 Sep 21 | 2,025 | 154 | 200 | 150 |
| 30 Jun 21 | 2,025 | 113 | 198 | 149 |
| 31 Mar 21 | 2,070 | 117 | 198 | 150 |
| 31 Dec 20 | 2,005 | 95 | 198 | 151 |
| 30 Sep 20 | 2,217 | 143 | 208 | 158 |
| 30 Jun 20 | 2,173 | 103 | 215 | 161 |
| 31 Mar 20 | 2,186 | 104 | 229 | 160 |
| 31 Dec 19 | 2,199 | 114 | 232 | 155 |
| 30 Sep 19 | 2,052 | -4 | 229 | 141 |
| 30 Jun 19 | 2,142 | 83 | 229 | 131 |
| 31 Mar 19 | 2,098 | 100 | 218 | 122 |
| 31 Dec 18 | 2,044 | 95 | 216 | 116 |
| 30 Sep 18 | 1,996 | 177 | 223 | 113 |
| 30 Jun 18 | 1,919 | 129 | 218 | 107 |
| 31 Mar 18 | 1,841 | 142 | 187 | 102 |
| 31 Dec 17 | 1,795 | 86 | 169 | 101 |
| 30 Sep 17 | 1,692 | -90 | 144 | 98 |
| 30 Jun 17 | 1,617 | -110 | 124 | 96 |
| 31 Mar 17 | 1,706 | -103 | 142 | 97 |
| 31 Dec 16 | 1,763 | 3 | 138 | 93 |
| 30 Sep 16 | 1,874 | 209 | 149 | 96 |
| 30 Jun 16 | 1,941 | 316 | 149 | 99 |
| 31 Mar 16 | 1,855 | 292 | 141 | 101 |
| 31 Dec 15 | 1,847 | 262 | 144 | 102 |
| 30 Sep 15 | 1,863 | 271 | 143 | 103 |
| 30 Jun 15 | 1,821 | 224 | 140 | 105 |
| 31 Mar 15 | 1,840 | 248 | 137 | 102 |
| 31 Dec 14 | 1,789 | 273 | 130 | 105 |
| 30 Sep 14 | 1,648 | 220 | 118 | 106 |
| 30 Jun 14 | 1,674 | 209 | 115 | 104 |
| 31 Mar 14 | 1,728 | 307 | 110 | 109 |
| 31 Dec 13 | 1,829 | 371 | 110 | 109 |
Quality Earnings: 1733 has high quality earnings.
Growing Profit Margin: 1733's current net profit margins (5.8%) are lower than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1733 has become profitable over the past 5 years, growing earnings by 8% per year.
Accelerating Growth: 1733's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1733 had negative earnings growth (-27.2%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.7%).
Return on Equity
High ROE: 1733's Return on Equity (5.9%) is considered low.